These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
352 related articles for article (PubMed ID: 32821149)
1. Clinical Utility of CYP2C19 Genotype-Guided Antiplatelet Therapy in Patients at Risk of Adverse Cardiovascular and Cerebrovascular Events: A Review of Emerging Evidence. Gower MN; Ratner LR; Williams AK; Rossi JS; Stouffer GA; Lee CR Pharmgenomics Pers Med; 2020; 13():239-252. PubMed ID: 32821149 [TBL] [Abstract][Full Text] [Related]
2. Clinical Utility of CYP2C19 Genotyping to Guide Antiplatelet Therapy in Patients With an Acute Coronary Syndrome or Undergoing Percutaneous Coronary Intervention. Klein MD; Williams AK; Lee CR; Stouffer GA Arterioscler Thromb Vasc Biol; 2019 Apr; 39(4):647-652. PubMed ID: 30760018 [TBL] [Abstract][Full Text] [Related]
3. Pharmacogenetics of P2Y Thomas CD; Williams AK; Lee CR; Cavallari LH Pharmacotherapy; 2023 Feb; 43(2):158-175. PubMed ID: 36588476 [TBL] [Abstract][Full Text] [Related]
5. Clinical Outcomes and Sustainability of Using Lee CR; Sriramoju VB; Cervantes A; Howell LA; Varunok N; Madan S; Hamrick K; Polasek MJ; Lee JA; Clarke M; Cicci JD; Weck KE; Stouffer GA Circ Genom Precis Med; 2018 Apr; 11(4):e002069. PubMed ID: 29615454 [TBL] [Abstract][Full Text] [Related]
6. Impact of the CYP2C19*17 Allele on Outcomes in Patients Receiving Genotype-Guided Antiplatelet Therapy After Percutaneous Coronary Intervention. Lee CR; Thomas CD; Beitelshees AL; Tuteja S; Empey PE; Lee JC; Limdi NA; Duarte JD; Skaar TC; Chen Y; Cook KJ; Coons JC; Dillon C; Franchi F; Giri J; Gong Y; Kreutz RP; McDonough CW; Stevenson JM; Weck KE; Angiolillo DJ; Johnson JA; Stouffer GA; Cavallari LH; Clin Pharmacol Ther; 2021 Mar; 109(3):705-715. PubMed ID: 32897581 [TBL] [Abstract][Full Text] [Related]
7. Economic Evaluations of CYP2C19 Genotype-Guided Antiplatelet Therapy Compared to the Universal Use of Antiplatelets in Patients With Acute Coronary Syndrome: A Systematic Review. AlMukdad S; Elewa H; Al-Badriyeh D J Cardiovasc Pharmacol Ther; 2020 May; 25(3):201-211. PubMed ID: 32027168 [TBL] [Abstract][Full Text] [Related]
8. CYP2C19 LOF and GOF-Guided Antiplatelet Therapy in Patients with Acute Coronary Syndrome: A Cost-Effectiveness Analysis. Jiang M; You JH Cardiovasc Drugs Ther; 2017 Feb; 31(1):39-49. PubMed ID: 27924429 [TBL] [Abstract][Full Text] [Related]
9. Impact of Implementing CYP2C19 Genotype-Guided Antiplatelet Therapy on P2Y Zhang Y; Shi XJ; Peng WX; Han JL; Lin BD; Zhang R; Zhang YN; Yan JL; Wei JJ; Wang YF; Chen SW; Nan N; Fang ZW; Zeng Y; Lin Y Front Pharmacol; 2020; 11():582929. PubMed ID: 33551797 [No Abstract] [Full Text] [Related]
10. Cost-effectiveness of CYP2C19-guided antiplatelet therapy in patients with acute coronary syndrome and percutaneous coronary intervention informed by real-world data. Limdi NA; Cavallari LH; Lee CR; Hillegass WB; Holmes AM; Skaar TC; Pisu M; Dillon C; Beitelshees AL; Empey PE; Duarte JD; Diaby V; Gong Y; Johnson JA; Graves J; Garbett S; Zhou Z; Peterson JF; Pharmacogenomics J; 2020 Oct; 20(5):724-735. PubMed ID: 32042096 [TBL] [Abstract][Full Text] [Related]
12. Clinical outcomes of CYP2C19 genotype-guided antiplatelet therapy: existing evidence and future directions. Klein MD; Lee CR; Stouffer GA Pharmacogenomics; 2018 Aug; 19(13):1039-1046. PubMed ID: 30028231 [TBL] [Abstract][Full Text] [Related]
13. Evaluation of race and ethnicity disparities in outcome studies of Nguyen AB; Cavallari LH; Rossi JS; Stouffer GA; Lee CR Front Cardiovasc Med; 2022; 9():991646. PubMed ID: 36082121 [TBL] [Abstract][Full Text] [Related]
14. Development of a routine bedside CYP2C19 genotype assessment program for antiplatelet therapy guidance in a community hospital catheterization laboratory. Gurbel PA; Bliden K; Sherwood M; Taheri H; Tehrani B; Akbari M; Yazdani S; Asgar JA; Chaudhary R; Tantry US J Thromb Thrombolysis; 2024 Apr; 57(4):566-575. PubMed ID: 38480590 [TBL] [Abstract][Full Text] [Related]
15. Frequency and clinical outcomes of CYP2C19 genotype-guided escalation and de-escalation of antiplatelet therapy in a real-world clinical setting. Martin J; Williams AK; Klein MD; Sriramoju VB; Madan S; Rossi JS; Clarke M; Cicci JD; Cavallari LH; Weck KE; Stouffer GA; Lee CR Genet Med; 2020 Jan; 22(1):160-169. PubMed ID: 31316169 [TBL] [Abstract][Full Text] [Related]